Answers are grounded in this paper and cite their sources.
Combination therapy with INK128 and palbociclib is effective against HNSCC xenografts. A, Tumor growth curve for HN12 xenografts treated with INK128, palbociclib, and combination (mean ± SEM, n = 10). B, Hematoxylin and eosin staining of HN12 xenograft tumors. C, BrdU staining for HN12 xenograft tumors. The percentage of BrdU-positive cells was compared by treatment group (mean ± SEM, n = 3). D, Representative IHC staining images of HN12 xenografts (strongly magnified). Tumors were stained with hematoxylin–eosin (HE), pS6, p4EBP1, CCND1, and CCNE1. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05, ns, nonsignificant. P value was determined using one-way ANOVA with the Tukey post hoc test in A and C. (Created with BioRender.com.)
No takes yet. Share an insight, caveat, or question.
Goto et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: